Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0279 • ACR Convergence 2021
Macrophage Cholesterol Loading Associates with Low-density Lipoprotein Structure, Oxidation, Antibodies Against Oxidized Epitopes and Is Modified by Immunomodulatory Treatments in Patients with Rheumatoid Arthritis
George Karpouzas¹, Bianca Papotti², sarah ormseth³, Marcella Palumbo⁴, Elizabeth Hernandez³, Cinzia Marchi⁴, Francesca Zimetti⁴, Franco Bernini⁴ and Nicoletta Ronda⁴, ¹Harbor-UCLA Medical Center, Torrance, CA, ²2. Department of Food and Drug, University of Parma, Italy, Parma, Italy, ³The Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, ⁴Department of Food and Drug, University of Parma, Parma, Italy
Background/Purpose: In Rheumatoid arthritis (RA), immune dysregulation, excess inflammation and oxidative stress may alter lipoprotein level and function and promote LDL oxidation and its uptake…
Abstract Number: 0354 • ACR Convergence 2021
A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus
Kathryn Starzyk¹, Gary Curhan² and Julia Brault², ¹OM1, Inc, Boston, MA, ²OM1, Boston, MA
Background/Purpose: Features of autoimmune conditions may coexist in individual patients, which may represent an overlapping single disease with features of both (i.e., ‘rhupus’), or the…
Abstract Number: 0527 • ACR Convergence 2021
Role of Terminal Uridylyl Transferase 7 in TNF-α-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts In Vitro
Anil singh, farheen Shaikh and Salah-uddin Ahmed, Washington State University, Spokane, WA
Background/Purpose: Terminal uridylyl transferase 7 (TUT7), also known as Zcchc6, is a zinc finger domain-containing protein responsible for terminal uridylation of miRNA, implicated in pre-miRNA…
Abstract Number: 0581 • ACR Convergence 2021
Rheumatoid Arthritis Treatment Patterns in Massachusetts: Informative Findings from Insurance Claims Data
Mark Matza¹, D. Steven Fox², Kay Larholt³, David Fritsche³, Elizabeth Apgar³, Mitesh Puthran³, Gigi Hirsch³ and Marcy Bolster¹, ¹Massachusetts General Hospital, Boston, MA, ²University of Southern California, School of Pharmacy, Los Angeles, CA, ³Massachusetts Institute of Technology (MIT) Center for Biomedical Innovation, Cambridge, MA
Background/Purpose: A real-world current state of RA patients in Massachusetts (MA) is analyzed to provide a novel assessment of demographics, treatment patterns, and clinical settings…
Abstract Number: 0609 • ACR Convergence 2021
Challenges of Caring for Patients with Inflammatory Arthritis Experiencing Homelessness: Preliminary (12- Month) Follow-up Observations and Identification of Certain Barriers to Care
Baljeet Rai¹, Nicole Zagelbaum Ward², Abhimanyu Amarnani², Corinne Feldman², Brett Feldman² and Richard Panush², ¹LAC+USC Medical Center, Modesto, CA, ²LAC+USC Medical Center, Los Angeles, CA
Background/Purpose: Homelessness is a public health crisis. Those with housing insecurity have unique barriers to healthcare that confound their outcomes. Because of the paucity of…
Abstract Number: 0788 • ACR Convergence 2021
Red Cell Distribution Width Is Associated with Baseline 25-hydroxyvitamin D Level Before Methotrexate Therapy in Rheumatoid Arthritis
Shahdi Malakooti¹, Brigid Wilson², Taissa Bej², Lenche Kostadinova³, Alyssa Lange², Megan O'Mara², David Zidar², Maya Mattar⁴ and Donald Anthony⁵, ¹Case Western Reserve University, UH Cleveland Medical Center, VA Medical Center, Cleveland, OH, ²VA Medical Center, Cleveland, OH, ³UH Cleveland Medical Center, VA Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Mayfield Heights, OH, ⁵Case, VA, Metro, Chardon, OH
Background/Purpose: Peripheral blood red cell distribution width (RDW) correlates with disease activity in rheumatoid arthritis (RA) and is associated with subsequent mortality in non-RA patient…
Abstract Number: 0805 • ACR Convergence 2021
A Real-world Prospective Observational Study of the Effectiveness of Golimumab in Adult Greek Patients with RA, PsA and Axial SpA and Inadequate Response to Initial TNFα Inhibitor Therapy
Panagiotis Athanassiou¹, Dimitrios Psaltis², Athanasios Georgiadis³, Gkikas Katsifis⁴, Athina Theodoridou⁵, Souzana Gazi⁶, Prodromos Sidiropoulos⁷, Maria Tektonidou⁸, Andreas Bounas⁹, Anna Kandyli¹⁰, Periklis Vounotrypidis⁵, Grigorios Sakellariou⁵, Dimitrios Vassilopoulos¹¹, Zhiping Huang¹², Evangelia Petrikkou¹³ and Dimitrios Boumpas¹⁴, ¹Department of Rheumatology, St. Paul’s Hospital of Thessaloniki, Thessaloniki, Greece, ²Private Practice, Serres, Greece, Athens, Greece, ³Private Practice, Ioannina, Greece, Athens, Greece, ⁴Rheumatology Clinic Naval Hospital of Athens, Athens, Greece, ⁵Private Practice, Thessaloniki, Greece, Athens, Greece, ⁶“KAT” Regional General Hospital, Rheumatology Unit, Athens, Greece, Athens, Greece, ⁷Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, Heraklion, Greece, ⁸Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Joint Rheumatology Program, Laiko Hospital, Athens, Greece, ⁹General Clinic of Patras “Olympion”, Rheumatology, Patras, Greece, ¹⁰Rheumatology Outpatient Clinic, Iaso General Hospital, Athens, Greece, ¹¹2nd University Department of Internal Medicine, General Hospital of Athens "Ippokrateion", Athens, Greece, ¹²Merck & Co., Inc., Pharmacoepidemiology, Center for Observational and Real-world Evidence (CORE), Kenilworth, NJ, ¹³MSD Pharmaceutical, Industrial and Commercial S.A, Athens, Medical Affairs, Athens, Greece, ¹⁴Rheumatology and Clinical Immunology, 4th Department of Internal Medicine, ‘‘Attikon’’ University Hospital, Athens, Greece
Background/Purpose: Patients (pts) with immune-mediated rheumatic diseases and an insufficient response to previous treatment with TNFα inhibitors (TNFαi) are frequently encountered in clinical practice. This…
Abstract Number: 0824 • ACR Convergence 2021
Physicians’ Reasons for Prescribing Janus Kinase Inhibitors (JAKi) in Patients with Rheumatoid Arthritis, and Associated Alignment Between Physicians and Patients in a Real-world Clinical Setting
Peter C Taylor¹, Bruno Fautrel², Yves Piette³, Susana Romero-Yuste⁴, Jasper Broen⁵, Martin Welcker⁶, Elizabeth Holdsworth⁷, Monia Zignani⁸, Katrien Van Beneden⁸, Roberto Caporali⁹ and Rieke Alten¹⁰, ¹University of Oxford, Oxford, United Kingdom, ²Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ³AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium, ⁴Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ⁵Maxima Medical Centre, Veldhoven, Netherlands, ⁶MVZ für Rheumatologie, Planegg, Germany, ⁷Adelphi Real World, Bollington, United Kingdom, ⁸Galapagos, NV, Mechelen, Belgium, ⁹Policlinico S. Matteo University, Pavia, Italy, ¹⁰Schlosspark-Klinik University, Berlin, Germany
Background/Purpose: Shared decision making, a cornerstone of rheumatoid arthritis (RA) management1, allows physicians and their patients to make informed decisions about their treatment goals and…
Abstract Number: 0840 • ACR Convergence 2021
Modelling of Disease Activity in Patients with Inflammatory Arthropathies Treated with Etanercept Originator or Biosimilar as First-Line Biologic: A Real-World Observational Study Using the OPAL Dataset
Claire Deakin¹, Geoffrey Littlejohn², Hedley Griffiths³, Tegan Smith⁴, Catherine OSullivan⁵ and Paul Bird⁶, ¹OPAL Rheumatology Ltd, Sydney, Australia, ²Monash University, Melbourne, Australia, ³Barwon Rheumatology Service, Geelong, Australia, ⁴OPAL Rheumatology Ltd, Kogarah, Australia, ⁵OPAL Rheumatology Ltd, Queenscliff, Australia, ⁶University of New South Wales, Sydney, Australia
Background/Purpose: The availability of biosimilars as non-proprietary versions of established biologic disease-modifying anti-rheumatic drugs (bDMARDs) has increased around the world. Since April 2017 both the…
Abstract Number: 0990 • ACR Convergence 2021
Lower Incidence of COVID-19 but Higher Mortality in Patients with Inflammatory Arthritis Compared to Controls in Wales, United Kingdom: A Population Epidemiological Study
Roxanne Cooksey¹, Mark Atkinson² and Ernest Choy³, ¹Cardiff University, Cardiff, Wales, United Kingdom, ²Swansea University, Swansea, Wales, United Kingdom, ³CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: The COVID-19 pandemic has caused over 3 million deaths. Having inflammatory arthritis (IA) and anti-rheumatic medications increase the risk of infections. Comorbidities, common in…
Abstract Number: 1073 • ACR Convergence 2021
In Favor of the Subspecialty Clinic Model for Rheumatoid Arthritis
Jasmine Thai¹, Roshan Patel¹, Yeohan Song¹ and Sheryl Mascarenhas², ¹Ohio State University, Columbus, OH, ²Ohio State University Hospital, Columbus, OH
Background/Purpose: The Subspecialty Clinic Model (SCM) which seeks to allow for collaborative care and services by stratifying patients with a particular disease or need to…
Abstract Number: 1200 • ACR Convergence 2021
Predicting Progression to RA in Patients with Seropositive Arthralgia
Aine Gorman¹, Keelin Flynn², Matthew Turk¹, Candice Low³, Kieran Murray⁴, Carl Orr⁵, Phil Gallagher⁵, Lorna Freeman², Edel Meaney², Eamonn Molloy⁶, Lorraine O Neill⁷, Ursula Fearon⁸ and Douglas Veale⁹, ¹St Vincents Hospital, Dublin, Ireland, ²The Centre for Arthritis and Rheumatic Disease, EULAR Centre of Excellence, St. Vincent’s University Hospital and University College Dublin, Ireland, Dublin, Ireland, ³St. Vincent's University Hospital, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin, Ireland, ⁵St Vincent's Hospital, Dublin, Ireland, ⁶St Vincent's Healthcare Group, Dublin, Ireland, ⁷St. Vincent's Hospital, Dublin, Ireland, ⁸Trinity College Dublin, Dublin, Ireland, ⁹University College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory condition often associated with joint destruction, disability, and reduced life expectancy. Before RA diagnosis, some patients may…
Abstract Number: 1216 • ACR Convergence 2021
Evidence of a Tendency for Localized Recurrence of Arthritis in Rheumatoid Arthritis Patients
Sascha Heckert¹, Sytske Anne Bergstra¹, Xanthe Matthijssen¹, Yvonne Goekoop-Ruiterman², Faouzia Fodili³, Saskia ten Wolde⁴, Cornelia F. Allaart¹ and Tom WJ Huizinga¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²HagaZiekenhuis, The Hague, Netherlands, ³Stichting ReumaZorg ZWN, Roosendaal, Netherlands, ⁴Spaarne Gasthuis, Haarlem, Netherlands
Background/Purpose: Local inflammation may cause synovial fibroblasts to become sensitized, resulting in higher susceptibility to arthritis. Longitudinal assessment of joint involvement in rheumatoid arthritis (RA)…
Abstract Number: 1232 • ACR Convergence 2021
Synovial Tissue Lymphoid Aggregates Are Associated with Response to Rituximab Therapy in Rheumatoid Arthritis Patients
Matthew Turk¹, Candice Low², Carl Orr³, Richard Conway⁴, Kieran Murray⁵, Ursula Fearon⁶ and Douglas Veale⁷, ¹St. Vincents University Hospital, Dublin, Ireland, ²St. Vincent's University Hospital, Dublin, Ireland, ³St Vincent's Hospital, Dublin, Ireland, ⁴St. James's University Hospital, Dublin, Ireland, ⁵Saint Vincent's University Hospital, Dublin, Ireland, ⁶Trinity College Dublin, Dublin, Ireland, ⁷University College Dublin, Dublin, Ireland
Background/Purpose: Activated B lymphocytes and plasma cells are implicated in the pathogenesis of rheumatoid arthritis (RA). The anti-CD20 monoclonal antibody therapy (Rituximab) is an effective…
Abstract Number: 1248 • ACR Convergence 2021
Adjusted Analyses of the Benefits of Autoantibody Enrichment on Efficacy Outcomes in Early RA, from a Pooled Analysis of 4 Abatacept RCTs
Janet Pope¹, Sang Hee Park², Mirko Fillbrunn³, Karissa Lozenski², Vadim Khaychuk², Kaleb Michaud⁴, James Signorovitch³, Henry Lane³, Ha Nguyen³ and Philip Conaghan⁵, ¹University of Western Ontario, London, ON, Canada, ²Bristol Myers Squibb, Princeton, NJ, ³Analysis Group, Inc., Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Previous studies have found differential treatment efficacy of abatacept (ABA) for the treatment of RA based on biomarker-seropositivity.1-4 An earlier study found a differential…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].